Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
复制标题
DOI：
10.1200/jco.2005.13.524
复制
发表时间：
2005-08-01
影响因子：
45.3
通讯作者：
Cavalli, F
中科院分区：
文献类型：
--
作者：
Abrey, LE;Batchelor, TT;Cavalli, F
原发性CNS淋巴瘤（PCNSL）基线评价和缓解评估的标准化指南对于确保新诊断患者临床试验的可比性至关重要。这种肿瘤的相对罕见性排除了快速完成大规模III期试验的可能性，因此，我们对精心设计的II期试验结果的依赖至关重要。为了制定这一建议，代表血液肿瘤学、内科肿瘤学、神经肿瘤学、神经病学、放射肿瘤学、神经外科学和眼科学的国际专家组开会审查现行报告标准，并就最低基线评价和评估治疗反应的通用标准达成共识。反应指南基于神经影像学、皮质类固醇使用、眼科检查和CSF细胞学的结果。需要进一步研究的一个关键问题是评估治疗的神经认知影响和解决PCNSL幸存者生活质量的最佳方法。我们希望这些指南将改善研究者之间的沟通和临床试验之间的可比性，使我们能够为患者开发更好的治疗方法。
Standardized guidelines for the baseline evaluation and response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparability among clinical trials for newly diagnosed patients. The relative rarity of this tumor precludes rapid completion of large-scale phase III trials and, therefore, our reliance on the results of well-designed phase II trials is critical. To formulate this recommendation, an international group of experts representing hematologic oncology, medical oncology, neuro-oncology, neurology, radiation oncology, neurosurgery, and ophthalmology met to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy. The response guidelines were based on the results of neuroimaging, corticosteroid use, ophthalmologic examination, and CSF cytology. A critical issue that requires additional study is the optimal method to assess the neurocognitive impact of therapy and address the quality of life of PCNSL survivors. We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients.